fbpx
Big Law

US top court rejects Amgen over cholesterol medication patent fight

Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Read the source article at channelnewsasia.com

Leave a Review or Comment

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close